<DOC>
	<DOCNO>NCT00004212</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness DX-8951f treating child advance solid tumor lymphomas respond previous therapy .</brief_summary>
	<brief_title>DX-8951f Treating Children With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose exatecan mesylate ( DX-8951f ) without filgrastim ( G-CSF ) pediatric patient advance solid tumor lymphomas . - Determine toxic effect , include dose-limiting toxicity , exatecan mesylate patient . - Determine pharmacokinetics exatecan mesylate patient . - Determine recommend dose exatecan mesylate phase II study . - Determine antitumor activity regimen patient . OUTLINE : This dose-escalation study exatecan mesylate ( DX-8951f ) . Patients stratify accord prior treatment ( minimally treat vs heavily treat ) . Patients receive exatecan mesylate IV 30 minute daily 5 day . Patients dose level 5 also receive filgrastim ( G-CSF ) subcutaneously begin day 6 continue least 7 day blood count recover . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 1-6 patient receive escalate dos exatecan mesylate without G-CSF maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : Approximately 45 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Exatecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor , include brain tumor lymphomas , fail standard therapy ( surgery , radiotherapy , endocrine therapy , chemotherapy ) standard therapy exist Histology requirement waive brain stem gliomas PATIENT CHARACTERISTICS : Age : 21 diagnosis Performance status : ECOG 02 Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count least 750/mm^3 Platelet count least 75,000/mm^3 Hemoglobin least 8.5 g/dL Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis ) Renal : Creatinine great 1.5 time ULN OR GFR least 70 mL/min Other : Not pregnant nursing Negative pregnancy test No history severe lifethreatening hypersensitivity camptothecin analog HIV negative No concurrent severe uncontrolled medical illness No systemic infection PRIOR CONCURRENT THERAPY : Biologic therapy : Recovered prior immunotherapy Chemotherapy : See Disease Characteristics Recovered prior chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics At least 4 week since prior extensive radiotherapy involve cranial , whole pelvic , least 25 % bone marrow reserve Recovered prior radiotherapy Concurrent localize radiotherapy pain allow Surgery : See Disease Characteristics Recovered prior surgery Other : No concurrent antitumor therapy No concurrent drug induce inhibit CYP3A enzyme</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>untreated childhood visual pathway hypothalamic glioma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
</DOC>